Ventura & Associates HTA Advisors Advances Tech-enabled Solution with 3-Year RWD Partnership
The Californer/10286593

LOS ANGELES - Californer -- Ventura & Associates HTA Advisors, a California-based strategy consulting and tech-enabled solutions firm, has announced a landmark 3-year agreement with the National Clinical Trials Network (NCTN) to accelerate the development of an innovative clinical research analysis tool. This strategic partnership will leverage the power of real-world data (RWD) to drive groundbreaking discoveries and deeper insights into the understanding and treatment of complex medical conditions.

By combining the company's expertise in data-driven solutions with the NCTN's extensive clinical research network, this collaboration promises to revolutionize the way medical breakthroughs are achieved. The advanced analytics platform being developed will augment researchers' abilities to uncover patterns, trends and correlations within vast datasets, unlocking unprecedented opportunities for innovation.

More on The Californer

• Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
• California: Here's how Trump's illegal military deployment weakens firefighting resources – already strained by his dangerous U.S. Forest Service cuts
• THE INTERNATIONAL SCHOOL OF SAN FRANCISCO APPOINTS ERIC THUAU AS ITS NEXT HEAD OF SCHOOL
• Project Home Draws Up a Blueprint for Hope on Documentary Showcase
• California: Governor Newsom pre-deploys safety resources ahead of anticipated demonstrations

Ventura, CEO, has been incubating the project, stating, "We are honored to partner with the NCTN and that they see merit in the research to in turn leverage our collective capabilities to advance the frontiers of clinical research. The data acquired under this agreement spans five oncology studies will play a critical role in validating the design of the product and really bringing the plans to life. We are working on a second agreement to obtain more, relevant RWD areas in other therapeutic areas specifically in Diabetes and Alzheimer's Disease due to the adherence challenges and use of quality-of-life outcomes, as well as other studies with complex designs. We later plan to present our findings in the interim at a conferences during the terms of the agreements. We are actively seeking investors and additional research partners in Pharma & Biotech. All research and data management are HIPAA-compliant."

This agreement solidifies the start-up's position as a leading provider of tech-enabled solutions in the pharmaceutical industry. The partnership with major, global pharmaceutical companies positions the company at the forefront of innovation. This strategic alliance underscores the company's commitment to making meaningful strides in the pre-seed stage and its mission to remain committed to patient centricity and positive change.

More on The Californer

• TEAM HUSSLE: The Unstoppable Duo Redefining the Sound of the Streets
• City of Long Beach to Celebrate Grand Reopening of Martin Luther King Jr. Park Pool
• Celestix Launches InstaSafe Zero Trust on Microsoft Azure Marketplace
• Governor Newsom: Trump handed over Californians' personal information to Homeland Security, a dangerous violation of privacy
• LABOR BOARD ISSUES ANOTHER COMPLAINT AGAINST AMAZON

The company is currently seeking early stage investors globally as it accelerates the development of the tech-enabled solution to the minimum viable product (MVP) stage by end of Q2 2025. The company plans to subsequently continue research in predictive modeling and AI. The company sees a noteworthy market opportunity for correlo given the heightened focus on AI and drug development over the past year.

For more information visit the available websites:
Company Website, Latest Investor Presentation
LinkedIn